Lunsumio (mosunetuzumab-axgb) - Roche
LUNSUMIO injection Drug Use Surveillance (Relapsed or Refractory Follicular Lymphoma) (UMIN-CTR) - Oct 25, 2026 - P=N/A | N=120 | Active, not recruiting | Sponsor: Chugai Pharmaceutical Co. Ltd. | Recruiting ➔ Active, not recruiting 
Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000065660
 
Oct 25, 2026
 
Prev Next